When short seller Andrew Left of Citron Research characterized DuPont spinoff Chemours as a company “purposely designed for bankruptcy” and “a zero” in early June, his comments sent the NYSE-listed company tumbling over 20%. After all, less than a year ago, Left caused an almost crippling investor stampede from Valeant Pharmaceuticals VRX +0.88% when he published a report accusing the drugmaker of being “Enron part Deux.”
